Lumin Health is not currently in-network with Kaiser Permanente, including Kaiser Permanente Mid-Atlantic States (KPMAS) plans. We apologize that we can't accept KPMAS coverage; self-pay treatment at our Bethesda location remains an option.
KPMAS is structured as a closed-network HMO system. KPMAS does not publish a public Spravato-specific clinical criteria document — Spravato is administered through KP's medical benefit, not the pharmacy formulary. For most KPMAS members, accessing Spravato means working through Kaiser's own psychiatry team (Mid-Atlantic Permanente Medical Group).
Quick self-check by KPMAS plan type — see the plan-by-plan table below for what each plan generally allows for care outside Kaiser.
Latest medical review on: September 15th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
KPMAS does not publish a Spravato-specific clinical criteria document. The 'four AD trials' figure that appears in third-party summaries is from Kaiser Permanente Northwest, not KPMAS, and KP Northwest's standard is actually three antidepressant trials plus three augmentation therapies. KPMAS administers Spravato through the medical benefit, with criteria managed internally by Mid-Atlantic Permanente Medical Group (MAPMG) psychiatry teams.
What matters far more for a KPMAS member than the clinical criteria is which plan type you have — because that determines whether you can receive care outside Kaiser at all. Lumin Health is not in-network with any KPMAS plan type; the table below reflects KPMAS plan documents, not Lumin Health acceptance.
| Your KPMAS plan | Care outside Kaiser? | How |
|---|---|---|
| Out-of-Area PPO | Out-of-network benefit | OON benefit applies; precertification still required through KPMAS Behavioral Health Utilization Management; balance-billing risk applies. |
| Flexible Choice / Triple Option | Via Option 2 or 3 | Option 2: PHCS/MultiPlan or Cigna PPO network. Option 3: out-of-network with member cost-share. |
| HMO Plus / DHMO Plus | Limited | Members have a 10–15 OON visits/year cap (per KPMAS plan documents). A Spravato induction course exhausts this cap in 4–6 weeks. OON spend doesn't accrue to your in-network out-of-pocket maximum. |
| Signature / Select / FEHB HMO | Unlikely without referral | KPMAS HMO members “should obtain an approved referral from their primary care physician (PCP)” for external psychiatry per Provider Manual Ch. 14 §14.1. KPMAS structurally routes Spravato candidates internally to MAPMG psychiatry first. |
| Medicare Advantage / Maryland Medicaid | No | External provider access not covered. |
Note: Lumin Health delivers Spravato (esketamine) — FDA-approved nasal spray — and intramuscular (IM) ketamine. Lumin Health does not deliver intravenous (IV) ketamine. Kaiser regions that publish IV-ketamine policies (e.g., Kaiser Permanente Washington) classify IV ketamine for depression as experimental/investigational and non-covered.
If you'd like to receive Spravato at Lumin Health, the practical path is switching to a plan Lumin Health accepts during open enrollment. Annual open enrollment varies by employer (typically October–November for January 1 effective). Federal employees on KPMAS via FEHB have Open Season each November–December. Mental-health diagnosis is generally not a qualifying life event — you'll need to wait for the annual window. Plan ahead 6–12 months if Spravato is a near-term need.
The KPMAS 2026 FEHB brochure (RI 73-047) does not mention Spravato or esketamine anywhere across its 125 pages. Coverage falls under generic outpatient pharmacotherapy office-visit copays ($10/$20/$30 High/Standard/Prosper) and Section 5(f) specialty-tier drug copays ($100/$150/$200 per 30-day at Plan medical center pharmacy). The brochure's external-provider clause is unambiguous: “Unless you receive prior approval from us, Plan providers must provide or arrange your care. Call our Behavioral Health Access Unit at 866-530-8778 to make arrangements. If we are unable to provide services in our Plan facilities, you may request a referral to a network provider.” Without prior approval or a KPMAS referral, OON care is “All charges” (member pays 100%).
Two Maryland insurance statutes apply when a commercial carrier reviews a Spravato prior authorization:
Step therapy prohibition for non-FDA-approved alternatives. Under Maryland Insurance Article §15-142, a commercial carrier may not require step therapy when (a) the step-therapy drug is not FDA-approved for the condition being treated, or (b) the prescriber documents that a covered drug ordered for the same condition within the past 180 days was clinically effective. For Spravato — FDA-approved specifically for treatment-resistant depression — this means a carrier cannot require trials of drugs not FDA-approved for TRD as a precondition.
Grievance and adverse-decision review. Under Maryland Insurance Article §15-10A-02, commercial carriers must issue a standard adverse-determination decision within 30 working days, an emergency review within 24 hours, and a behavioral-health emergency-admission review within 2 hours. After internal review, members can request external review through the Maryland Insurance Administration: 120-day filing window, 60-day decision (4 business days for emergencies).
Lumin Health is not in-network with Kaiser Permanente, so we do not submit prior authorizations or appeals to Kaiser Permanente Mid-Atlantic States. For Spravato through your KPMAS plan, KPMAS Behavioral Health Utilization Management (301-552-1212) and the Behavioral Health Access Unit (866-530-8778) are the places to start.
If you'd still like to receive care at Lumin Health's Bethesda location, self-pay treatment may be an option; call 240-348-6090 to talk through it. If you switch to a plan Lumin Health accepts, such as Aetna, CareFirst BCBS, Cigna, or UnitedHealthcare, our team handles insurance verification and prior authorization on your behalf.
Spravato treatment at Lumin Health in the Maryland/DMV area is available at our Bethesda location, which serves patients from across Maryland, the District of Columbia, and Northern Virginia. The Bethesda location is REMS-certified per FDA requirements.
Lumin Health is not in-network with Kaiser Permanente Mid-Atlantic. For comparison, here is how the Maryland commercial plans Lumin Health accepts handle published Spravato prior authorization criteria:
| Criterion | Aetna | CareFirst BCBS | Cigna | UnitedHealthcare |
|---|---|---|---|---|
| Failed AD trials required | 2 (different classes, 8wk each) | 2 (different classes, 8wk each) | 2 (different classes; ≤25% improvement) | 2 (8wk each; reduced from 3 in 3/2025) |
| Augmentation requirement | 1 of 4 named (or evidence-based psychotherapy) | 5 forms accepted (lithium, T3, buspirone, SGAs, AD combos) | Not required | Not required |
| Combination with oral AD (TRD) | Not required | Required (with augmentation) | Not required | Not required (as of 3/2025) |
| Initial / reauth duration | 6-month reauth | 1 month initial / 3 month continuation | 6-month extensions | 12 months initial / 12 months reauth |
| Quantity limit | Per Aetna CPB 0950 dosing schedule | Per CVS Caremark 2889-A | Per IP0220; 84mg max single dose | Per UHC 2168-10 |
| Submission method | Aetna Specialty Pharmacy 866-752-7021 / fax 888-267-3277 | CVS Caremark portal / Specialty Guideline Mgmt | Per IP0220 | UHC commercial PA portal |
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
No. KPMAS does not publish a public Spravato-specific clinical criteria document. The ‘four antidepressant trials’ figure that appears in third-party summaries is from Kaiser Permanente Northwest, not KPMAS, and KP Northwest's standard is technically three antidepressant trials plus three augmentation therapies. KPMAS administers Spravato through the medical benefit, with criteria managed internally by MAPMG psychiatry teams.
Only as a self-pay patient. Lumin Health is not in-network with Kaiser Permanente, including KPMAS plans. KPMAS structurally routes Spravato candidates to MAPMG psychiatry first, so Kaiser's own team is usually the most direct covered path. The other options are switching to a plan Lumin Health accepts at open enrollment, or self-pay treatment at Lumin Health.
No. Lumin Health is not currently in-network with Kaiser Permanente, and that includes every KPMAS plan type (Signature, Select, HMO Plus, Flexible Choice, Out-of-Area PPO, FEHB, and Medicare Advantage). Self-pay treatment is available at Lumin Health's Bethesda location. If you're unsure which plan you have, the member-services number on your Kaiser card can confirm it.
Janssen's Spravato withMe program has two parts: a Savings Program (covers medicine cost) and an Observation Rebate Program (covers session/observation cost), for commercially insured patients. Spravato withMe excludes Medicare, Medicaid, TRICARE, VA, and DoD members, and SaveOnSP-partnered plans are ineligible. Annual program caps apply; call 844-4S-WITHME to confirm your eligibility and current limits.
Annual open enrollment is the practical window. For employer-sponsored plans, this is usually October–November for January 1 effective. For Federal Employees Health Benefits members on KPMAS, Open Season is November–December. Mental-health diagnosis is generally not a qualifying life event — plan 6–12 months ahead if Spravato is a near-term clinical need. If your employer offers a non-Kaiser option that Lumin Health accepts, such as Aetna, CareFirst BCBS, Cigna, or UnitedHealthcare, that's typically the simplest switch.
Step 1 — File a Level 1 internal appeal. Deadline: 180 calendar days from receipt of the denial notice (per Kaiser: "Your appeal must be filed in writing within 180 calendar days of your receipt of our denial letter. The 180 days count starting 5 business days from the date of the notice to allow for mail delivery time, unless you can prove that you received the notice after that 5-business day period."). The 5-business-day mail-delivery construction is unusual — most other payers count from the date of the notice itself. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Kaiser Foundation Health Plan, Member Relations - Appeals, Nine Piedmont Center, 3495 Piedmont Road NE, Atlanta, GA 30305-1736. Phone: 888-225-7202 (appeals discussion line) or 800-777-7902 (Member Services; TTY 711). For Spravato-specific routing: KPMAS Behavioral Health Utilization Management 301-552-1212 (fax 855-414-1703).
Step 2 — Peer-to-peer (P2P) review. Kaiser Permanente operates a closed integrated delivery system — for Kaiser members seeing Kaiser-employed clinicians, peer-to-peer is conducted within Permanente Medical Group rather than through external escalation. For care outside Kaiser, denials are typically benefits-based (no out-of-network coverage on your specific plan type) rather than medical-necessity-based, and the appeal argument changes accordingly.
Step 3 — Expedited (urgent) appeal. Kaiser must resolve expedited (urgent) appeals within 72 hours when delay jeopardizes the member's health. Call 800-777-7902 (TTY 711) and explicitly request expedited review with documented medical urgency.
Appeal levels. Kaiser MAS provides multiple internal appeal levels with a standard 30-day timeline at each level. Specific level structure depends on your plan type (Out-of-Area PPO, Flexible Choice, HMO Plus, Signature/Select HMO, FEHB).
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Maryland external review is administered by the Maryland Insurance Administration (MIA). Filing window: 120 days from the final internal denial. Decision timeline: 60 days standard, 4 business days for emergencies. See Maryland state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Kaiser MAS does not vendor behavioral-health appeals to a separate company — appeals are handled internally by KPMAS Member Relations. For care outside Kaiser, set realistic expectations: Kaiser HMO members typically lack out-of-network behavioral-health coverage outside Kaiser facilities, so an appeal for outside care usually argues either (a) medical necessity for an out-of-network exception or (b) plan-type-specific OON allowance (e.g., Out-of-Area PPO). The likelihood of overturning a benefits-based denial is materially lower than overturning a medical-necessity denial. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
A note on Lumin Health. Lumin Health is not in-network with Kaiser Permanente and does not file prior authorizations or appeals with Kaiser Permanente Mid-Atlantic States. For help with a KPMAS denial, contact KPMAS Member Relations at the numbers above, or the Maryland Insurance Administration for external review.
